Olumiant regulatory update

Eli Lilly and Incyte said the European Commission approved Olumiant baricitinib to treat moderate to severe active rheumatoid arthritis in adults who have not responded adequately to, or are intolerant of, disease-modifying anti-rheumatic drugs (DMARDs). The approval is the first in the world for Olumiant and the first in the EU for a Janus kinase (JAK) inhibitor to treat RA, Lilly said. The pharma expects to launch the drug gradually in 2017 as it completes discussions with local reimbursement officials...